A few weeks ago, I published a surface-level review of CURI, ranking it as “Highest Priority” while placing it behind a paywall and redacting the name for free subscribers. It was clear from the start that unless a major red flag emerged during the deep dive process, this would be the focus of my next write-up.
Fast forward to today, CURI is already up ~30%, having increased its dividend by 20%. Yet, it remains a classic low risk, high uncertainty opportunity, offering strong downside protection and unlimited potential for upside surprises. There’s no time to waste, so let’s dive in.
IMPORTANT NOTE: To the best of my knowledge, CURI is now under increasing scrutiny, with more institutional eyeballs closely watching.
Scroll down to download the full report and model.
